Selected research
Industry Research
Mitogen Activated Protein Kinase 14 Industry Research Report 2026
Market perspective
The global Mitogen Activated Protein Kinase 14 market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Mitogen Activated Protein Kinase 14 is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Mitogen Activated Protein Kinase 14 is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Mitogen Activated Protein Kinase 14 is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Mitogen Activated Protein Kinase 14 include Eli Lilly and Company, GlaxoSmithKline Plc, AstraZeneca Plc, Zocere, Inc., Toray Industries, Synovo GmbH, Chroma Therapeutics Limited, Chiesi Farmaceutici SpA and Astellas Pharma Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Mitogen Activated Protein Kinase 14 market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Mitogen Activated Protein Kinase 14 Market by Company
Eli Lilly and Company
GlaxoSmithKline Plc
AstraZeneca Plc
Zocere, Inc.
Toray Industries
Synovo GmbH
Chroma Therapeutics Limited
Chiesi Farmaceutici SpA
Astellas Pharma Inc.
Array BioPharma Inc.
Mitogen Activated Protein Kinase 14 Segment by Type
Ralimetinib Mesylate
Neflamapimod
Losmapimod
CHF-6297
Others
Mitogen Activated Protein Kinase 14 Segment by Application
Gastric Cancer
Epithelial Ovarian Cancer
Chronic Inflammation
Ulcerative Colitis
Others
Mitogen Activated Protein Kinase 14 Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mitogen Activated Protein Kinase 14 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Mitogen Activated Protein Kinase 14 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mitogen Activated Protein Kinase 14.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Mitogen Activated Protein Kinase 14 manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Mitogen Activated Protein Kinase 14 by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Mitogen Activated Protein Kinase 14 in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Ralimetinib Mesylate
- Neflamapimod
- Losmapimod
- CHF-6297
- Others
Applications
- Gastric Cancer
- Epithelial Ovarian Cancer
- Chronic Inflammation
- Ulcerative Colitis
- Others
Companies covered
- Eli Lilly and Company
- GlaxoSmithKline Plc
- AstraZeneca Plc
- Zocere, Inc.
- Toray Industries
- Synovo GmbH
- Chroma Therapeutics Limited
- Chiesi Farmaceutici SpA
- Astellas Pharma Inc.
- Array BioPharma Inc.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Mitogen Activated Protein Kinase 14 Market Size (2021-2032)
- 2.2.2 Global Mitogen Activated Protein Kinase 14 Sales (2021-2032)
- 2.2.3 Global Mitogen Activated Protein Kinase 14 Market Average Price (2021-2032)
- 2.3 Mitogen Activated Protein Kinase 14 by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Ralimetinib Mesylate
- 2.3.3 Neflamapimod
- 2.3.4 Losmapimod
- 2.3.5 CHF-6297
- 2.3.6 Others
- 2.4 Mitogen Activated Protein Kinase 14 by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Gastric Cancer
- 2.4.3 Epithelial Ovarian Cancer
- 2.4.4 Chronic Inflammation
- 2.4.5 Ulcerative Colitis
- 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Mitogen Activated Protein Kinase 14 Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Mitogen Activated Protein Kinase 14 Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Mitogen Activated Protein Kinase 14 Revenue of Manufacturers (2021-2026)
- 3.4 Global Mitogen Activated Protein Kinase 14 Average Price by Manufacturers (2021-2026)
- 3.5 Global Mitogen Activated Protein Kinase 14 Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Mitogen Activated Protein Kinase 14, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Mitogen Activated Protein Kinase 14, Product Type & Application
- 3.8 Global Manufacturers of Mitogen Activated Protein Kinase 14, Established Date
- 3.9 Global Mitogen Activated Protein Kinase 14 Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Eli Lilly and Company
- 4.1.1 Eli Lilly and Company Company Information
- 4.1.2 Eli Lilly and Company Business Overview
- 4.1.3 Eli Lilly and Company Mitogen Activated Protein Kinase 14 Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Eli Lilly and Company Mitogen Activated Protein Kinase 14 Product Portfolio
- 4.1.5 Eli Lilly and Company Recent Developments
- 4.2 GlaxoSmithKline Plc
- 4.2.1 GlaxoSmithKline Plc Company Information
- 4.2.2 GlaxoSmithKline Plc Business Overview
- 4.2.3 GlaxoSmithKline Plc Mitogen Activated Protein Kinase 14 Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 GlaxoSmithKline Plc Mitogen Activated Protein Kinase 14 Product Portfolio
- 4.2.5 GlaxoSmithKline Plc Recent Developments
- 4.3 AstraZeneca Plc
- 4.3.1 AstraZeneca Plc Company Information
- 4.3.2 AstraZeneca Plc Business Overview
- 4.3.3 AstraZeneca Plc Mitogen Activated Protein Kinase 14 Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 AstraZeneca Plc Mitogen Activated Protein Kinase 14 Product Portfolio
- 4.3.5 AstraZeneca Plc Recent Developments
- 4.4 Zocere, Inc.
- 4.4.1 Zocere, Inc. Company Information
- 4.4.2 Zocere, Inc. Business Overview
- 4.4.3 Zocere, Inc. Mitogen Activated Protein Kinase 14 Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Zocere, Inc. Mitogen Activated Protein Kinase 14 Product Portfolio
- 4.4.5 Zocere, Inc. Recent Developments
- 4.5 Toray Industries
- 4.5.1 Toray Industries Company Information
- 4.5.2 Toray Industries Business Overview
- 4.5.3 Toray Industries Mitogen Activated Protein Kinase 14 Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Toray Industries Mitogen Activated Protein Kinase 14 Product Portfolio
- 4.5.5 Toray Industries Recent Developments
- 4.6 Synovo GmbH
- 4.6.1 Synovo GmbH Company Information
- 4.6.2 Synovo GmbH Business Overview
- 4.6.3 Synovo GmbH Mitogen Activated Protein Kinase 14 Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Synovo GmbH Mitogen Activated Protein Kinase 14 Product Portfolio
- 4.6.5 Synovo GmbH Recent Developments
- 4.7 Chroma Therapeutics Limited
- 4.7.1 Chroma Therapeutics Limited Company Information
- 4.7.2 Chroma Therapeutics Limited Business Overview
- 4.7.3 Chroma Therapeutics Limited Mitogen Activated Protein Kinase 14 Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Chroma Therapeutics Limited Mitogen Activated Protein Kinase 14 Product Portfolio
- 4.7.5 Chroma Therapeutics Limited Recent Developments
- 4.8 Chiesi Farmaceutici SpA
- 4.8.1 Chiesi Farmaceutici SpA Company Information
- 4.8.2 Chiesi Farmaceutici SpA Business Overview
- 4.8.3 Chiesi Farmaceutici SpA Mitogen Activated Protein Kinase 14 Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Chiesi Farmaceutici SpA Mitogen Activated Protein Kinase 14 Product Portfolio
- 4.8.5 Chiesi Farmaceutici SpA Recent Developments
- 4.9 Astellas Pharma Inc.
- 4.9.1 Astellas Pharma Inc. Company Information
- 4.9.2 Astellas Pharma Inc. Business Overview
- 4.9.3 Astellas Pharma Inc. Mitogen Activated Protein Kinase 14 Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Astellas Pharma Inc. Mitogen Activated Protein Kinase 14 Product Portfolio
- 4.9.5 Astellas Pharma Inc. Recent Developments
- 4.10 Array BioPharma Inc.
- 4.10.1 Array BioPharma Inc. Company Information
- 4.10.2 Array BioPharma Inc. Business Overview
- 4.10.3 Array BioPharma Inc. Mitogen Activated Protein Kinase 14 Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Array BioPharma Inc. Mitogen Activated Protein Kinase 14 Product Portfolio
- 4.10.5 Array BioPharma Inc. Recent Developments
5 Global Mitogen Activated Protein Kinase 14 Market Scenario by Region
- 5.1 Global Mitogen Activated Protein Kinase 14 Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Mitogen Activated Protein Kinase 14 Sales by Region: 2021-2032
- 5.2.1 Global Mitogen Activated Protein Kinase 14 Sales by Region: 2021-2026
- 5.2.2 Global Mitogen Activated Protein Kinase 14 Sales by Region: 2027-2032
- 5.3 Global Mitogen Activated Protein Kinase 14 Revenue by Region: 2021-2032
- 5.3.1 Global Mitogen Activated Protein Kinase 14 Revenue by Region: 2021-2026
- 5.3.2 Global Mitogen Activated Protein Kinase 14 Revenue by Region: 2027-2032
- 5.4 North America Mitogen Activated Protein Kinase 14 Market Facts & Figures by Country
- 5.4.1 North America Mitogen Activated Protein Kinase 14 Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Mitogen Activated Protein Kinase 14 Sales by Country (2021-2032)
- 5.4.3 North America Mitogen Activated Protein Kinase 14 Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Mitogen Activated Protein Kinase 14 Market Facts & Figures by Country
- 5.5.1 Europe Mitogen Activated Protein Kinase 14 Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Mitogen Activated Protein Kinase 14 Sales by Country (2021-2032)
- 5.5.3 Europe Mitogen Activated Protein Kinase 14 Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Mitogen Activated Protein Kinase 14 Market Facts & Figures by Country
- 5.6.1 Asia Pacific Mitogen Activated Protein Kinase 14 Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Mitogen Activated Protein Kinase 14 Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Mitogen Activated Protein Kinase 14 Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Mitogen Activated Protein Kinase 14 Market Facts & Figures by Country
- 5.7.1 South America Mitogen Activated Protein Kinase 14 Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Mitogen Activated Protein Kinase 14 Sales by Country (2021-2032)
- 5.7.3 South America Mitogen Activated Protein Kinase 14 Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Mitogen Activated Protein Kinase 14 Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Mitogen Activated Protein Kinase 14 Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Mitogen Activated Protein Kinase 14 Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Mitogen Activated Protein Kinase 14 Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Mitogen Activated Protein Kinase 14 Sales by Type (2021-2032)
- 6.1.1 Global Mitogen Activated Protein Kinase 14 Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Mitogen Activated Protein Kinase 14 Sales Market Share by Type (2021-2032)
- 6.2 Global Mitogen Activated Protein Kinase 14 Revenue by Type (2021-2032)
- 6.2.1 Global Mitogen Activated Protein Kinase 14 Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Mitogen Activated Protein Kinase 14 Revenue Market Share by Type (2021-2032)
- 6.3 Global Mitogen Activated Protein Kinase 14 Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Mitogen Activated Protein Kinase 14 Sales by Application (2021-2032)
- 7.1.1 Global Mitogen Activated Protein Kinase 14 Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Mitogen Activated Protein Kinase 14 Sales Market Share by Application (2021-2032)
- 7.2 Global Mitogen Activated Protein Kinase 14 Revenue by Application (2021-2032)
- 7.2.1 Global Mitogen Activated Protein Kinase 14 Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Mitogen Activated Protein Kinase 14 Revenue Market Share by Application (2021-2032)
- 7.3 Global Mitogen Activated Protein Kinase 14 Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Mitogen Activated Protein Kinase 14 Value Chain Analysis
- 8.1.1 Mitogen Activated Protein Kinase 14 Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Mitogen Activated Protein Kinase 14 Production Mode & Process
- 8.2 Mitogen Activated Protein Kinase 14 Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Mitogen Activated Protein Kinase 14 Distributors
- 8.2.3 Mitogen Activated Protein Kinase 14 Customers
9 Global Mitogen Activated Protein Kinase 14 Analyzing Market Dynamics
- 9.1 Mitogen Activated Protein Kinase 14 Industry Trends
- 9.2 Mitogen Activated Protein Kinase 14 Industry Drivers
- 9.3 Mitogen Activated Protein Kinase 14 Industry Opportunities and Challenges
- 9.4 Mitogen Activated Protein Kinase 14 Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst